Altamira Therapeutics Ltd CYTOF

$0.10 +0.03 (41.24%)

Valuation

Market cap
405,000
Revenue TTM
$0
Net income TTM
$-2,960,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.37

Trading

Volume
4,001
Avg volume
6,684
Day's range
$0.10 – $0.10
Shares out
5,715,000
Stochastic %K
24%
Beta
1.93
Analysts
—
Price target
—

Price

Company profile

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland, Australia, the United States, and Europe. The company develops and supplies peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues through xPhore platform; and offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens It is also developing AM-401...

Show more

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland, Australia, the United States, and Europe. The company develops and supplies peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues through xPhore platform; and offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens It is also developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; and AM-125 that is in post phase II clinical trial for the intranasal treatment of vertigo. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.

Industry
Biotechnology
Sector
Healthcare
Phone
441 295 5950
Website
https://altamiratherapeutics.com
Address
Clarendon House, 2 Church Street, Hamilton, Bermuda

Latest news

No headlines yet.

Stocktwits

Cashflow62 Jun 11, 1:10 PM
$CYTOF https://www.otcmarkets.com/stock/CYTOF/news/Altamira-Therapeutics-to-Present-at-Formulation-and-Delivery-Europe-Conference?id=524158
0 replies
StocktwitsEarnings Mar 31, 3:02 PM
$CYTOF Q2 '25 Earnings Results & Recap Altamira Therapeutics reported a net loss of $3M for 2025, an improvement from $8.5M in the prior year, with operating loss decreasing to $4.4M and loss per share at $0.55.
0 replies
StocktwitsEarnings Mar 31, 3:02 PM
$CYTOF Q2 '25 Earnings Results & Recap Altamira expects its operating expenses to decrease significantly in 2026, following the planned spin-off of its ATAG subsidiary and termination of US SEC reporting duties, with updated guidance to follow.
0 replies
Cashflow62 Feb 13, 2:02 PM
$CYTOF Altamira Therapeutics Announces Allowance of Japanese Patent Application Covering Bentrio Nasal Spray.
0 replies
Cashflow62 Jan 23, 2:12 PM
$CYTOF https://finance.yahoo.com/news/altamira-therapeutics-present-mrna-based-140000849.html
0 replies
Cashflow62 Jan 9, 4:16 PM
$CYTOF Best bid in months......
1 replies
Cashflow62 Dec 19, 2:31 PM
$CYTOF Altamira Therapeutics Announces Market Approval of Bentrio Nasal Spray in China.....news out.
0 replies
stefano93 Dec 8, 7:26 AM
$CYTOF still not bankrupt? Damn.
0 replies